Document is current
Any future updates will be listed below
-
Authors
Ota, Eri
Tanaka, Hidekazu
Mochizuki, Yasuhide
Yamauchi, Yuki
Shiraki, Hiroaki
Yamashita, Kentaro
Shono, Ayu
Suzuki, Makiko
Sumimoto, Keiko
Yokoi, Aisha
Urai, Shin
Hirota, Yushi
Ogawa, Wataru
Hirata, Ken-ichi
- License Information
-
More Information
Article History
Received: 16 January 2022
Accepted: 30 March 2022
First Online: 23 April 2022
Declarations
:
: Hidekazu Tanaka is a consultant for AstraZeneca plc and Ono Pharmaceutical Company, Limited. Yushi Hirota is a consultant for Eli Lilly and Company. Wataru Ogawa is a consultant for Sumitomo Dainippon Pharma Co., Ltd. Wataru Ogawa has received research funding from Sumitomo Dainippon Pharma Co., Ltd., Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk A/S, TEIJIN PHARMA LIMITED., and Takeda Pharmaceutical Company Limited. Ken-ichi Hirata has received research funding from Daiichi Sankyo Company, Limited, Actelion Pharmaceuticals Japan, Terumo Corporation, Abbott Vascular Japan, Otsuka Pharmaceutical Company, Limited, Kowa Company, Limited, Takeda Pharmaceutical Company Limited, Nihon Medi-Physics Company Limited, Novartis Pharma Company Limited, Bayer Company Limited, Biotronic Japan Company Limited, FUJIFILM Toyama Chemical Company Limited, Medtronic Japan Company Limited, Sysmex Company Limited. The remaining authors have no conflicts of interest to declare.
: This article does not contain any studies with human participants or animals.
